Published 26 October 2026. Written and edited by Yianni Kiromitis. Based on CBS News reporting published 21 October 2026 and independent regulatory sources. What’s in the Vial did not buy or test any samples.
A CBS News investigation reported strikingly different laboratory findings from three products marketed as retatrutide. Two purchased online produced results consistent with a basic retatrutide reference prepared by a researcher. A vial bought from a Brooklyn corner shop did not appear to contain a peptide: testing instead identified phenylacetic acid, and separate microbiological examination found 13 bacterial colonies. [1]
What CBS bought and what the laboratories reported
Correspondent Adam Yamaguchi purchased products sold as retatrutide through two US websites, including one associated with a wellness clinic and another with a gym. CBS described promises of clinical screening, but reported that the products were delivered without the correspondent speaking to a healthcare professional. He also bought a $90 vial from a Brooklyn convenience store bearing a label stating that it was for research use only and not for human consumption. [1]
| Reported source | Reported laboratory finding | Evidence boundary |
|---|---|---|
| Wellness-clinic website | Sample consistent with a basic retatrutide reference made by the University of Iowa researcher. | Does not independently establish exact content, purity, dose, sterility, stability or identity with Lilly’s trial product. |
| Gym-associated website | Sample also consistent with that basic reference. | Does not establish manufacturing standards or whether other vials from the seller would produce the same result. |
| Brooklyn corner shop | No peptide-like substance identified in the reported analysis; phenylacetic acid identified. Separate examination found 13 bacterial colonies. | The report does not provide a general contamination rate, bacterial species identification or the concentration of viable bacteria in a dose. |
University of Iowa research scientist Jason Galpin conducted the chemical work described by CBS. Carl Ross of the university’s Center for Biocatalysis and Bioprocessing reported the microbiological finding. Their comments were reported by the newsroom, rather than published as a complete laboratory methods paper in the materials available for this article. [1]
Why finding 13 colonies matters — and what the number cannot tell us
The reported finding of 13 bacterial colonies belongs to the single corner-shop sample. A colony is an observed growth result under the conditions of a microbiological test, not a bacterial species count or an automatic estimate of how many organisms would be delivered by an injection. CBS did not supply enough methodological detail in its report to calculate microbial burden per millilitre, identify the organisms or reconstruct the sample’s handling history. [1]
The result is nevertheless a substantial product-quality warning: injection products require controls against microbial contamination that a seller’s label cannot demonstrate. A chemical-identity result and a microbiological result answer different questions. The site’s sterility, endotoxin and microbial testing guide explains those distinctions without treating one test as a substitute for another. Our contamination and mislabelling guide covers the wider product-assurance problem.
Why the other two samples do not amount to a safety clearance
CBS described the two online samples as consistent with a basic reference made by Galpin. That wording matters. It is not equivalent to reporting that an accredited laboratory authenticated them against an official reference standard, quantified the contents, confirmed sterility or validated their shelf life. CBS expressly distinguished the basic standard from the material being evaluated in Eli Lilly’s clinical trials. [1]
The reported comparison therefore has value, but only within its stated analytical scope. Even a convincing identity result on a traceably identified vial could not establish attributes the method did not measure. Our method-to-claim guide explains how identity, quantity, purity and contamination require separate evidence.
The four evidence layers: label, certificate, laboratory test and clinical study
| Evidence layer | What it can establish here | What it cannot establish |
|---|---|---|
| 1. Label or seller description | What the retailer claims is in the product. | That the contents match the claim; a “research use only” label is not a quality certificate. |
| 2. Certificate of analysis | Potentially, specified results for a linked sample and batch, where the document and methods can be authenticated. | CBS’s account does not establish that any certificate verified all three products or that a document covered every required attribute. |
| 3. Independent laboratory analysis | The characteristics actually investigated in the particular submitted samples, subject to method and sampling limitations. | Unmeasured dose accuracy, sterility, stability or quality of different vials and batches. |
| 4. Clinical evidence | Outcomes and adverse effects observed with the investigational medicine in controlled research settings. | Safety, identity or clinical interchangeability of a separately sold product bearing the same name. |
Our analysis concerns the evidence boundary, not an endorsement of a product or laboratory. We did not observe the collection, shipping, chain of custody, instruments or full raw results. An independent reader should treat the CBS findings as reported analysis of selected purchases, not the results of testing performed by this publication.
What does this mean for readers in the UK?
The CBS purchases took place in the United States. The US FDA warns that products sold directly to consumers as retatrutide under research-only labels are unapproved and of uncertain quality. Its rules on US compounding should not be presented as UK law. [2]
For the UK, the relevant regulator is the MHRA. Our retatrutide evidence profile separately assesses the clinical-trial molecule, UK status and products sold outside trials. Its 15 October 2026 enforcement release says retatrutide is not authorised in the UK and warns that products marketed under that name outside legitimate clinical trials may have unverified contents and contamination. The MHRA’s separate Birmingham operation seized more than 12,000 fake weight-loss pens; it was not part of the CBS investigation, and neither report establishes a link between the sellers or their products. [3] Read our Birmingham seizure report for the UK incident and its own evidence limits.
Where to verify and report a suspected product
UK readers can report a suspected side effect or defective or falsified medicine through the MHRA Yellow Card Scheme. Suspected unlawful online sellers have a separate MHRA suspicious-seller reporting route. These are different reporting tasks; neither is a substitute for medical care. [4] [5]
Three questions the investigation answers — and three it does not
Does the report show a vial labelled retatrutide can contain something else?
Yes, within the sample analysed. CBS reported that the Brooklyn vial did not appear to contain a peptide and that phenylacetic acid was identified. That is a finding about this purchased sample, not a rate across the market. [1]
Were 13 types of bacteria identified?
No. The newsroom reported 13 bacterial colonies, not 13 distinct species. It did not publish bacterial identification details in the article. [1]
Do the two reference-consistent samples prove that online retatrutide is safe?
No. A limited chemical comparison is not a comprehensive quality assessment. It also cannot make an unapproved product clinically interchangeable with retatrutide used in a controlled trial. [1] [2]
The useful conclusion is narrower, and stronger, than a blanket headline: one analysed shop-bought vial was inconsistent with its label and yielded a microbiological warning; two other samples met only the limited chemical comparison described by CBS. Those differences are why each evidence claim must be kept attached to the specific test and sample.
Sources and reporting method
- Yamaguchi A, Geller L, and colleagues. We bought and tested what was sold as an experimental weight loss drug. CBS News, 21 October 2026. Original investigation and attributed University of Iowa laboratory findings. The report is journalistic, not a published laboratory methods paper.
- US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Relevant warnings on research-labelled products and investigational retatrutide. US regulatory context only.
- MHRA. Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police. 15 October 2026. UK authorisation status and a separate UK enforcement case.
- MHRA. Report a problem with a medicine or medical device. Suspected quality problems, falsification and adverse reactions.
- MHRA. Report a suspicious online seller of medicines. Separate suspected unlawful seller reporting route.
- Wilkins J. Someone Ran a Chemical Analysis of Bodega Retatrutide. Futurism, 24 October 2026. Secondary coverage; the CBS report is the main reporting source.
Sources reviewed 26 October 2026. This is independent evidence interpretation, not independent replication of laboratory testing. No commercial peptide supplier funded this reporting.